Neuroscience company set for Irish and UK listing
London-based neuroscience company Amarin Corporation is to seek secondary listings on the IEX
market of the Irish Stock Exchange and the AIM market of the London Stock Exchange.
Amarin will retain its primary listing on the Nasdaq and is not seeking any additional capital as part of the listing process.
Amarin has $33m (€26m) in cash as at March 31. Admission to AIM and IEX is expected to occur in mid July.
Davy is acting as nominated advisor (Nomad), IEX adviser and broker to Amarin in respect of the admission.
Amarin boss Rick Stewart said: "While the majority of our investors are based in the United States, AIM and IEX listings will offer greater flexibility to our existing and future European and international investors and will enhance our European visibility."
Amarin focused on the research, development and commercialisation of drugs for the treatment of central nervous system disorders.
